Darbepoetin alfa for the treatment of chemotherapy-induced anemia: Disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials

Journal of Clinical Oncology

Volumn 23, Issue 28, 2005, Pages 6941-6948

  Hedenus, Michael ^a   Vansteenkiste, Johan ^a   Kotasek, Dusan ^a   Austin, Matthew ^a   Amado, Rafael G ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR GROWTH; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; LUNG TUMOR; LYMPHOMA; MULTICENTER STUDY; SURVIVAL;

ANEMIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MALE; PLACEBOS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 27244443556     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.434     Document Type: Article

References (48)

1. Caro JJ, Salas M, Ward A, et al: Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 91:2214-2221, 2001
2. Glaser CM, Millesi W, Kornek GV, et al: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50:705-715, 2001
3. Grogan M, Thomas GM, Melamed I, et al: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86:1528-1536, 1999
4. Lee WR, Berkey B, Marcial V, et al: Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 42:1069-1075, 1998
5. Maestu I, Pastor M, Gomez-Codina J, et al: Pretreatment prognostic factors for survival in small-cell lung cancer: A new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 8:547-553, 1997
6. Moullet I, Salles G, Ketterer N, et al: Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 9:1109-1115, 1998
7. Munstedt K, Kovacic M, Zygmunt M, et al: Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol 23:837-843, 2003
8. Shasha D: The negative impact of anemia on radiotherapy and chemoradiation outcomes. Semin Hematol 38:8-15, 2001
9. Vaupel P, Thews O, Mayer A, et al: Oxygenation status of gynecologic tumors: What is the optimal hemoglobin level? Strahlenther Onkol 178:727-731, 2002
10. Brizel DM, Scully SP, Harrelson JM, et al: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941-943, 1996
11. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91, 1996
12. Hockel M, Schlenger K, Aral B, et al: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509-4515, 1996
13. Hockel M, Schlenger K, Hockel S, et al: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59:4525-4528, 1999
14. Hohenberger P, Felgner C, Haensch W, et al: Tumor oxygenation correlates with molecular growth determinants in breast cancer. Breast Cancer Res Treat 48:97-106, 1998
15. Kelleher DK, Mattheinsen U, Thews O, et al: Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 56:4728-4734, 1996
16. Teicher BA, Holden SA, al-Achi A, et al: Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50:3339-3344, 1990
17. Vaupel P, Hockel M: Oxygenation of human tumors, in Molls M, Vaupel P (eds): Blood Perfusion and Microenvironment of Human Tumors: Implications for Clinical Oncology. New York, NY, Springer-Verlag, 1998, pp 63-72
18. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41:31-39, 1996
19. Vaupel P, Thews O, Hoeckel M: Treatment resistance of solid tumors: Role of hypoxia and anemia. Med Oncol 18:243-259, 2001
20. Dubray B, Mosseri V, Brunin F, et al: Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study. Radiology 201:553-558, 1996
21. Fein DA, Lee WR, Hanlon AL, et al: Pre-treatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13:2077-2083, 1995
22. Fyles AW, Milosevic M, Wong R, et al: Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48:149-156, 1998
23. van Acht MJ, Hermans J, Boks DE, et al: The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 23:229-235, 1992
24. Warde P, O'Sullivan B, Bristow RG, et al: T1/T2 glottic cancer managed by external beam radiotherapy: The influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 41:347-353, 1998
25. Crawford J, Robert F, Perry MC, et al: Prevention of anemia with once weekly (QW) epoetin alfa in patients with nonsmall-cell lung cancer (NSCLC). Lung Cancer 41:374, 2003 (suppl)
26. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
27. Bohlius J, Langensiepen S, Schwarzer G, et al: Erythropoietin for patients with malignant disease [Cochrane Database System Review] Oxford, United Kingdom, Cochrane Library, CD003407, issue 3, 2004
28. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy. A survival study. J Clin Oncol 23:5960-5972, 2005
29. Henke M, Laszig R, Be C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260, 2003
30. Bokemeyer C, Aapro MS, Courdi A, et al: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201-2216, 2004
31. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100:2303-2320, 2002
32. Sabbatini P: Clinical practice guidelines in oncology: Cancer and treatment-related anemia, National Comprehensive Cancer Network, 2004. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
33. Epoetin: For better or worse? Lancet Oncol 5:1, 2004
34. Haddad R, Posner M: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363:79-80, 2004
35. Kaanders JH, van der Kogel AJ: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363:78-79, 2004
36. Leyland-Jones B, Mahmud S: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363:80, 2004
37. Machtay M, Pajak T, Suntharalingam M, et al: Definitive radiotherapy +/- erythropoietin for squamous cell carcinoma of the head and neck: Preliminary report of RTOG 99-03. Int J Radiat Oncol Biol Phys 60:S132, 2004 (suppl 1)
38. Möbus V, Untch M, Du Bois A, et al: Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN): First results of an AGO-trial. J Clin Oncol 22:6S, 2004 (suppl; abstr 513)
39. Österborg A, Brandberg Y, Hedenus M: Impact of epoetin-β on survival of patients with lymphoproliferative malignancies: Long-term follow up of a large randomized study. Br J Haematol 129:206-209, 2005
40. Egrie JC, Dwyer E, Browne JK, et al: Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299, 2003
41. Elliott S, Lorenzini T, Asher S, et al: Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21:414-421, 2003
42. Glaspy J, Tchekmedyian NS: Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology 16:23-29, 2002 (suppl 11)
43. Macdougall IC, Gray SJ, Elston O, et al: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392-2395, 1999
44. Vansteenkiste J, Pirker R, Massuti B, et al: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220, 2002
45. Hedenus M, Adriansson M, San Miguel J, et al: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 122:394-403, 2003
46. Kotasek A, Steger G, Faught W, et al: Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: Results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39:2026-2034, 2003
47. Hedenus M, Hansen S, Taylor K, et al: Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119:79-86, 2002
48. Briefing Package for the FDA Oncologic Drugs Advisory Committee Meeting, May 2004. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2.htm